OUR THERAPY
Clinical and Scientific Publications
Prospective Studies
Activated Charcoal Filtration Profoundly Alters Systemic Noradrenaline Concentrations During Hepatic Chemosaturation: A Prospective Cohort Study
2026 | Turra et al.
Percutaneous Hepatic Perfusion Combined with Ipilimumab and Nivolumab for Metastatic Uveal Melanoma (CHOPIN): A Single-Centre, Open-Label, Randomised Phase 2 Trial
2026 | van den Hoek et al.
Subgroup analyses of the phase 3 FOCUS study of melphalan/hepatic delivery system in patients with unresectable metastatic uveal melanoma
2025 | Zager et al.
An Open-label, Randomized Study of Melphalan/Hepatic Delivery System Versus Best Alternative Care in Patients with Unresectable Metastatic Uveal Melanoma
2025 | Zager et al.
Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 Study
2024 | Zager et al.
Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Ocular Melanoma Metastases Confined to the Liver: A Prospective Phase II Study
2020 | Meijer et al.
Prospective Clinical and Pharmacological Evaluation of the Delcath System’s Second-Generation (GEN2) Hemofiltration System in Patients Undergoing Percutaneous Hepatic Perfusion with Melphalan
2017 | de Leede et al.
Case Series & Cohort Studies
Percutaneous Hepatic Perfusion versus Best Alternative Care as Treatment for Metastatic Uveal Melanoma: A Meta-Analysis
2026 | van den Hoek et al.
Angiotensin II for the Treatment of Vasodilatory Shock during Percutaneous Hepatic Perfusion Cases: A Case Report
2026 | Andrew et al.
Characterization of long-term survivors with liver metastases from uveal melanoma diagnosed between 2005 and 2021
2025 | Laukhuf et al.
Predictive Parameters in Patients Undergoing Percutaneous Hepatic Perfusion with Melphalan for Unresectable Liver Metastases from Uveal Melanoma: A Retrospective Pooled Analysis
2025 | Tong et al.
Hepatic chemosaturation with melphalan in patients with primary or secondary liver tumors with or without extrahepatic tumor manifestation
2024 | Veelken et al.
Percutaneous Hepatic Perfusion (PHP) with Melphalan in Liver-Dominant Metastatic Uveal Melanoma: The German Experience
2022 | Dewald et al.
New Perspectives in Unresectable Cholangiocarcinoma? Evaluation of Chemosaturation with Percutaneous Hepatic Perfusion as a Palliative Treatment Option
2022 | Dewald et al.
Chemosaturation with percutaneous hepatic perfusion of melphalan for metastatic uveal melanoma
2022 | Modi et al.
Meta-Analysis of Isolated Hepatic Perfusion and Percutaneous Hepatic Perfusion as a Treatment for Uveal Melanoma Liver Metastases
2021 | Bethlehem et al.
Unresectable Hepatic Metastasis of Uveal Melanoma: Hepatic Chemosaturation with High-Dose Melphalan—Long-Term Overall Survival Negatively Correlates with Tumor Burden
2020 | Brüning et al.
Chemosaturation with percutaneous hepatic perfusion is effective in patients with ocular melanoma and cholangiocarcinoma
2020 | Schönfeld et al.
Chemosaturation with percutaneous hepatic perfusion of melphalan for liver-dominant metastatic uveal melanoma: a single center experience
2019 | Artzner et al.
Percutaneous Hepatic Perfusion with Melphalan in Uveal Melanoma: A Safe and Effective Treatment Modality in an Orphan Disease
2017 | Karydis et al.
Tolerability and Efficacy of Chemosaturation in Combination with Systemic Therapy for Metastatic Uveal Melanoma
2026 | Kasteleiner et al.
Procedural & Technical Publications
A Novel Flow Model for Demonstrating and Simulating Chemosaturation with Percutaneous Hepatic Perfusion in Unresectable Liver Metastasis
Silivasan et al., 2026
Reviews & Commentaries
Anesthetic Considerations and Management for the Percutaneous Hepatic Perfusion Procedure
2026 | Kozarek KL, et al.
Liver-Directed Therapies Can Be More Than “Local Tumor Control”
2026 | Collettini et al.
Synergistic Integration of Regional and Systemic Therapies in Uveal Melanoma
2026 | Shaheer A. Khan & Richard D. Carvajal
Treatment of Liver Metastases from Uveal Melanoma with Percutaneous Hepatic Perfusion
2025 | Padia et al.
Scientific Meetings
Phase 1b/2 Trial of Melphalan-Percutaneous Hepatic Perfusion (PHP) Therapy and Nivolumab/Relatlimab in Patients with Metastatic Melanoma and Liver Metastasis
ASCO 2026 | Ma et al.
Phase 2 Sequential Treatment of Percutaneous Hepatic Perfusion with Melphalan/Hepatic Delivery System Followed by Tebentafusp in the Treatment of Metastatic Uveal Melanoma
ASCO 2026 | Zager et al.
Safety and Feasibility of Percutaneous Hepatic Perfusion with Melphalan in Patients with Liver-Dominant Metastatic Breast Cancer
ESMO Breast 2026 | Dewald et al.
A Single-Center Preliminary Experience of Percutaneous Hepatic Perfusion with Melphalan for Liver Metastases of Uveal Melanoma
JVIR 2026 | Seker et al.
Percutaneous Hepatic Perfusion (PHP) with Melphalan for Treatment of Liver Metastases from Uveal Melanoma: Initial Commercial Experience
JVIR 2026 | Eschelman et al.
Melphalan/Hepatic Delivery System versus Best Available Care in Patients with Unresectable Metastatic Uveal Melanoma: Randomized FOCUS Trial Results
ASCO 2024 | Zager et al.
Isolated Hepatic Perfusion (IHP)
Survival and Quality of Life After Isolated Hepatic Perfusion With Melphalan as a Treatment for Uveal Melanoma Liver Metastases
2025 | Olofsson Bagge et al.